Eli Lilly and Company (LLY) Holdings Increased by Ledyard National Bank
Ledyard National Bank boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 35.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,404 shares of the company’s stock after buying an additional 1,150 shares during the period. Ledyard National Bank’s holdings in Eli Lilly and were worth $363,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Heritage Trust Co acquired a new stake in Eli Lilly and during the 1st quarter worth about $135,000. Point72 Asia Hong Kong Ltd raised its holdings in Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the period. Penserra Capital Management LLC raised its holdings in Eli Lilly and by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the period. American National Bank raised its holdings in Eli Lilly and by 5.2% during the 2nd quarter. American National Bank now owns 2,088 shares of the company’s stock worth $172,000 after buying an additional 104 shares during the period. Finally, Sandy Spring Bank raised its holdings in Eli Lilly and by 51.8% during the 1st quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after buying an additional 750 shares during the period. Hedge funds and other institutional investors own 75.72% of the company’s stock.
LLY has been the topic of a number of research reports. BidaskClub upgraded Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Barclays PLC upped their target price on Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. Berenberg Bank reiterated a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a report on Thursday, July 27th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 target price (up previously from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $88.27.
Shares of Eli Lilly and Company (NYSE LLY) traded up 0.207% during midday trading on Thursday, reaching $84.825. The company’s stock had a trading volume of 843,793 shares. The company has a 50-day moving average price of $80.84 and a 200-day moving average price of $82.02. The firm has a market cap of $89.49 billion, a price-to-earnings ratio of 36.705 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.86 EPS. Equities analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 190,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the transaction, the insider now owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 590,000 shares of company stock worth $48,551,300 in the last ninety days. Insiders own 0.20% of the company’s stock.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.